comparemela.com

Page 2 - Avidity Analyzer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

LUMICKS Unveils Groundbreaking New C-Trap Product at Biophysical Society Annual Meeting

New product line C-Trap 'Edge' brings unparalleled features relevant for surface assays, which are of increasing importance in biophysical and biological research AMSTERDAM, Feb. 22, 2022

United statesSan franciscoNoord hollandJos maasKostenloser wertpapierhandelJoshua youngKassandra barbetseaBiophysical society meetingAnnual biophysical society meetingC trap dymoGeneral managerDynamic single moleculeCell avidityLabel free microscopyAvidity analyzer

New Nature Paper Relies on LUMICKS C-Trap Technology to Understand Functionality of Key Protein Involved with Incorrect DNA Repair of Dangerous Lesions Linked to Cancer Predisposition

AMSTERDAM, Feb. 15, 2022 /PRNewswire/ LUMICKS, a leading life science tools company that develops equipment for dynamic single-molecule and cell avidity analysis, today announced that its

New yorkUnited statesCity ofUnited kingdomNoord hollandSimonj boultonSloan ketteringAndrea candelliKassandra barbetseaSimon powellDavid ruedaImperial college londonLondon institute of medical sciencesFrancis crick instituteMemorial sloan ketteringWeill cornell medical

LUMICKS: New study published in Translational Medicine highlights cell avidity s power as a functional biomarker for improved CAR-T design in preventing tumor escape

AMSTERDAM, Jan. 25, 2022 /PRNewswire/ LUMICKS, a next generation life science tools company, today announced that research findings from a consortium, led by researchers at Cancer Center

Noord hollandKostenloser wertpapierhandelJoshua youngMaria themeliAndrea candelliKassandra barbetseaAmsterdam university medical centersCancer center amsterdamScience translational medicineAvidity analyzerScience translationalMovi analyzerChief scientific officerDynamic single moleculeCell avidityLabel free microscopy

LUMICKS Raises $93 Million in Series D Financing

LUMICKS Raises $93 Million in Series D Financing - Backed by global investor syndicate led by new investors Farallon Capital Management and Lauxera Capital Partners along with Softbank Fund 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Gilde Healthcare, Pura Vida Investments, and Irving Investors AMSTERDAM, April 16, 2021 /PRNewswire/ LUMICKS, a leading, next-generation life science tools company that develops highly innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced the completion of a $93 million Series D preferred share financing. The funding round was led by new investors Farallon Capital Management and Lauxera Capital Partners, and included investments by Softbank Vision 2

France generalSan franciscoUnited statesNoord hollandKostenloser wertpapierhandelErwin petermanIddo hellerOlivier heyningKassandra barbetseaGijs wuiteWilliam blairSoftbank vision fundSoftbank fundSoftbank group corpT rowe price associatesFarallon capital management

vimarsana © 2020. All Rights Reserved.